BioRing MPT IVR
Cornell Vaginal Ring
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Undetermined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): BioRings, Weill Cornell Medicine
Details
- API: Tenofovir, Ferrous Gluconate
-
Mechanism of Action:
- Inhibition of Sperm Capacitation
- Anti-Microbial
- Inactive Materials: Hydrogel
- Regimen: Undetermined - Likely 1 Ring/Menstrual Cycle
- MPT: Potential MPT
- Promising Attributes: Developers suggest that a non-hormonal, hydrogel-based MPT might provide contraceptive and antimicrobial protection with limited side effects and vaginal irritation
Product Status
No Indication of Development after 2015. Developer is Inactive.
History
2004: Weill Cornell Medicine publishes results of animal evaluation for a hydrogel-based contraceptive ring, indicating that in rabbits, their prototype ring successfully decapacitated sperm.
2007: Researchers indicate that their prototype ring is capable of sustained release of both antimicrobial and contraceptive agents.
2009: Weill Cornell Medicine publishes confirmatory findings indicating sustained release of ARVs.
2015: BioRings announces partnership with QPharma for CMC support.